ORIGINAL RESEARCH article
Front. Pharmacol., 29 January 2020
Sec. Pharmacology of Anti-Cancer Drugs
Volume 10 - 2019 | https://doi.org/10.3389/fphar.2019.01658
RETRACTED: Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin
Shuhui Zhang 1†
Lin Zhou 1†
Mengdi Zhang 1
Yuehua Wang 1
Mengqi Wang 1
Jincheng Du 1,3
Wenwen Gu 1
Fuguang Kui 1
Jiahuan Li 1*
Shengnan Geng 2*
Gangjun Du 1,2*
1. Institute of Pharmacy, Pharmaceutical College of Henan University, Kaifeng, China
2. School of Pharmacy and Chemical Engineering, Zhengzhou University of Industry Technology, Xinzheng, China
3. Chinese Medical School, Hunan University of Chinese Medicine, Changsha, China
Summary
Citation
Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, Gu W, Kui F, Li J, Geng S and Du G (2020) RETRACTED: Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin. Front. Pharmacol. 10:1658. doi: 10.3389/fphar.2019.01658
Received
06 November 2019
Accepted
17 December 2019
Published
29 January 2020
Volume
10 - 2019
Edited by
Jiangjiang Qin, Zhejiang Chinese Medical University, China
Reviewed by
Dan Shao, South China University of Technology, China; Qiao Liu, Shandong University, China
Updates
†These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.